文献速递妇科生殖医学

药物治疗在子宫腺肌症管理中的作用

Role of medical therapy in the management of uterine adenomyosis.
PubMed 文献 · Fertil Steril · 2018-01-01

子宫腺肌症为良性子宫疾病,患者年龄与症状各异,管理仍存争议,针对药物或手术治疗的临床研究较少,目前无药物获批用于腺肌症且无特定指南可循;药物治疗对改善疼痛、异常子宫出血和不孕有效,依据为性激素异常、凋亡受损和炎症增加的发病机制。

要点

  • 非激素药物(如非甾体抗炎药)和激素药物(如孕激素、口服避孕药、促性腺激素释放激素类似物)目前超说明书用于控制腺肌症疼痛症状和异常子宫出血。
  • 促性腺激素释放激素类似物在不孕腺肌症女性生育治疗前使用,以提高妊娠机会。
  • 左炔诺孕酮释放宫内装置在长期管理计划中对解决异常子宫出血和缩小子宫体积极为有效。

核心结论

  • 药物治疗对改善腺肌症症状(疼痛、异常子宫出血和不孕)有效。
  • 目前无药物获批用于腺肌症,也无特定指南可循最佳管理。

研究设计与样本

  • 综述,聚焦药物治疗或手术治疗子宫腺肌症的临床研究较少。

主要发现

  • 药物治疗依据腺肌症发病机制:性激素异常、凋亡受损和炎症增加。
  • 非激素药物(如非甾体抗炎药)和激素药物(如孕激素、口服避孕药、促性腺激素释放激素类似物)目前超说明书用于控制疼痛症状和异常子宫出血。
  • 促性腺激素释放激素类似物在不孕腺肌症女性生育治疗前使用,以提高妊娠机会。
  • 孕激素(如地诺孕素、达那唑和醋酸炔诺酮)的抗增殖和抗炎作用提示其用于腺肌症药物管理,主要控制疼痛症状。
  • 左炔诺孕酮释放宫内装置在长期管理计划中对解决异常子宫出血和缩小子宫体积极为有效。

关键数值与推荐

  • 基于发病机制新发现,正在开发用于腺肌症治疗的新药,包括选择性孕激素受体调节剂、芳香化酶抑制剂、丙戊酸和抗血小板治疗。

临床怎么用

  • 非激素药物(如非甾体抗炎药)和激素药物(如孕激素、口服避孕药、促性腺激素释放激素类似物)目前超说明书用于控制腺肌症疼痛症状和异常子宫出血。
  • 促性腺激素释放激素类似物在不孕腺肌症女性生育治疗前使用,以提高妊娠机会。
  • 左炔诺孕酮释放宫内装置在长期管理计划中对解决异常子宫出血和缩小子宫体积极为有效。

局限性

  • 针对腺肌症药物或手术治疗的临床研究较少。
  • 目前无药物获批用于腺肌症,也无特定指南可循最佳管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adenomyosis is a benign uterine condition affecting women at various ages with different symptoms. The management of these patients is still controversial. Few clinical studies focusing on medical or surgical treatment for adenomyosis have been performed. No drug is currently labelled for adenomyosis and there are no specific guidelines to follow for the best management. Anyhow, medical treatments are effective in improving symptoms (pain, abnormal uterine bleeding and infertility). The rationale for using medical treatment is based on the pathogenetic mechanisms of adenomyosis: sex steroid hormones aberrations, impaired apoptosis, and increased inflammation. Several nonhormonal (i.e., nonsteroidal anti-inflammatory drugs) and hormonal treatments (i.e., progestins, oral contraceptives, gonadotropin-releasing hormone analogues) are currently used off-label to control pain symptoms and abnormal uterine bleeding in adenomyosis. Gonadotropin-releasing hormone analogues are indicated before fertility treatments to improve the chances of pregnancy in infertile women with adenomyosis. An antiproliferative and anti-inflammatory effect of progestins, such as dienogest, danazol and norethindrone acetate, suggests their use in medical management of adenomyosis mainly to control pain symptoms. On the other hand, the intrauterine device releasing levonorgestrel resulted is extremely effective in resolving abnormal uterine bleeding and reducing uterine volume in a long-term management plan. Based on new findings on pathogenetic mechanisms, new drugs are under development for the treatment of adenomyosis, such as selective progesterone receptor modulators, aromatase inhibitors, valproic acid, and anti-platelets therapy.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Vannuccini S, Luisi S, Tosti C, et al. Role of medical therapy in the management of uterine adenomyosis. Fertil Steril. 2018. PMID: 29566852. doi:10.1016/j.fertnstert.2018.01.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。